Menthol for PDT Pain Relief

This proposal describes the prospective randomised double blind, placebo controlled clinical trial that will be undertaken to investigate the use of topical menthol for PDT-induced pain relief in patients with actinic keratosis of the face and scalp who will be attending general dermatology and PDT outpatient clinics at Ninewells Hospital, Dundee.

This will be undertaken by comparison of 5% menthol in aqueous cream with aqueous cream as placebo and the primary outcome measures will be pain recorded on a visual analogue scale (VAS) during and up to 24 h after PDT. Secondary outcomes are phototoxicity, assessed by a semi-quantitative scoring system immediately after PDT, fluorescence assessed routinely after cream application and before irradiation and outcome based on clinical assessment three months after PDT and patient evaluation. Patients will be involved in the study from the first visit for PDT until the three-month assessment visit after PDT. Data analysis will be undertaken using within-subject paired analyses as patients act as their own control. Information from this study will inform investigators as to whether topical menthol should be routinely incorporated into PDT treatment regimens in order to reduce pain and increase tolerance of treatment. The information will also provide additional information as to the mechanisms of PDT-induced pain and its possible prevention and/or relief.

Inclusion criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

• Adults >18 years. Target population is men or women ≥50 years (only post-menopausal women)
• Presence of actinic keratoses (AK) on the face and scalp involving both right and left comparable sites.
• Free of significant physical abnormalities (e.g. tattoos, dermatoses) in the potential treatment area that may cause difficulty with examination or final evaluation.
• Able to understand and adhere to protocol requirements.

Exclusion criteria

• Unable to give written informed consent.
• Allergy to menthol, aqueous cream or excipients
• Participation in a drug trial or other interventional study within 30 days of recruitment to this study
• Pre-menopausal women, pregnancy, breast feeding, planning to conceive
• Chronic pain